Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Issue 12 (December 2022)

• Record Type: Journal Article
• Authors: Donnez, Jacques; Taylor, Hugh S.; Stewart, Elizabeth A.; Bradley, Linda; Marsh, Erica; Archer, David; Al-Hendy, Ayman; Petraglia, Felice; Watts, Nelson; Gotteland, Jean-Pierre; Bestel, Elke; Terrill, Paul; Loumaye, Ernest; Humberstone, Andrew; Garner, Elizabeth
• Is Part Of: Obstetrical & gynecological survey. Volume 77:Issue 12(2022)
• Page Start: 741
• Page End: 742
• Publication Date: 2022-12
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/OGX.0000000000001113
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from Lancet 2022;400:896–907) Uterine fibroids occur in 50% to 60% of women and are symptomatic in 30% of patients by causing abnormal uterine bleeding and pelvic pressure. Treatment of uterine fibroids involves surgical and radiological interventions, as well as progestogens and other medical therapies.